JP2019520340A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019520340A5 JP2019520340A5 JP2018562993A JP2018562993A JP2019520340A5 JP 2019520340 A5 JP2019520340 A5 JP 2019520340A5 JP 2018562993 A JP2018562993 A JP 2018562993A JP 2018562993 A JP2018562993 A JP 2018562993A JP 2019520340 A5 JP2019520340 A5 JP 2019520340A5
- Authority
- JP
- Japan
- Prior art keywords
- faecalibacterium
- pharmaceutical composition
- microbial preparation
- purified
- growth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241001608234 Faecalibacterium Species 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 230000000813 microbial Effects 0.000 claims 12
- 229940100691 Oral Capsule Drugs 0.000 claims 8
- 230000002550 fecal Effects 0.000 claims 7
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims 6
- 241000605909 Fusobacterium Species 0.000 claims 5
- 229960002433 Cysteine Drugs 0.000 claims 3
- RWSXRVCMGQZWBV-WDSKDSINSA-N Glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims 3
- 229960003180 Glutathione Drugs 0.000 claims 3
- 108010024636 Glutathione Proteins 0.000 claims 3
- 206010021972 Inflammatory bowel disease Diseases 0.000 claims 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 3
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-Acetylglucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims 3
- 229950006780 N-Acetylglucosamine Drugs 0.000 claims 3
- 229960002477 Riboflavin Drugs 0.000 claims 3
- AUNGANRZJHBGPY-OUCADQQQSA-N Riboflavin Natural products OC[C@@H](O)[C@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-OUCADQQQSA-N 0.000 claims 3
- 241000192031 Ruminococcus Species 0.000 claims 3
- 235000018417 cysteine Nutrition 0.000 claims 3
- 235000013325 dietary fiber Nutrition 0.000 claims 3
- 235000003969 glutathione Nutrition 0.000 claims 3
- 235000010987 pectin Nutrition 0.000 claims 3
- 229920001277 pectin Polymers 0.000 claims 3
- 239000001814 pectin Substances 0.000 claims 3
- 229960000292 pectin Drugs 0.000 claims 3
- 235000019192 riboflavin Nutrition 0.000 claims 3
- 239000002151 riboflavin Substances 0.000 claims 3
- 241000702460 Akkermansia Species 0.000 claims 2
- 241000701474 Alistipes Species 0.000 claims 2
- 241000894006 Bacteria Species 0.000 claims 2
- 241000606125 Bacteroides Species 0.000 claims 2
- 241000605947 Roseburia Species 0.000 claims 2
- 241001531188 [Eubacterium] rectale Species 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000000021 stimulant Substances 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 210000000936 Intestines Anatomy 0.000 claims 1
- 230000003115 biocidal Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003324 growth hormone secretagogue Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001225 therapeutic Effects 0.000 claims 1
- 201000006704 ulcerative colitis Diseases 0.000 claims 1
Claims (23)
- 精製されたＦａｅｃａｌｉｂａｃｔｅｒｉｕｍ株と精製されたＯｄｏｒｉｂａｃｔｅｒ ｓｐｌａｎｃｈｎｉｃｕｓを含む糞便微生物調製物を含む凍結乾燥薬学的組成物を含む経口カプセルであって、前記糞便微生物調製物が、Ｆｕｓｏｂａｃｔｅｒｉｕｍ属及びＲｕｍｉｎｏｃｏｃｃｕｓ属を欠き、前記糞便微生物調製物が、Ｆａｅｃａｌｉｂａｃｔｅｒｉｕｍ増殖刺激剤の存在下でＦｕｓｏｂａｃｔｅｒｉｕｍの増殖を阻害またはアンタゴナイズし、前記精製されたＦａｅｃａｌｉｂａｃｔｅｒｉｕｍ株と前記Ｏｄｏｒｉｂａｃｔｅｒ ｓｐｌａｎｃｈｎｉｃｕｓの少なくとも1種は、健康なヒトドナーの便から由来する、経口カプセル。
- 前記Ｆａｅｃａｌｉｂａｃｔｅｒｉｕｍ株が、Ｆａｅｃａｌｉｂａｃｔｅｒｉｕｍ ｐｒａｕｓｎｉｔｚｉｉを含む、請求項１に記載の経口カプセル。
- 前記増殖刺激剤が、リンゴペクチン、Ｎ−アセチルグルコサミン、システイン、グルタチオン、リボフラビン、およびフラビンからなる群から選択される、請求項１に記載の経口カプセル。
- 前記増殖刺激剤を含む、請求項１に記載の経口カプセル。
- 前記糞便微生物調製物が、複数の精製されたＦａｅｃａｌｉｂａｃｔｅｒｉｕｍ株を含む、請求項１に記載の経口カプセル。
- 前記糞便微生物調製物が、Ｅｕｂａｃｔｅｒｉｕｍ ｒｅｃｔａｌｅ、Ａｋｋｅｒｍａｎｓｉａ属、Ａｌｉｓｔｉｐｅｓ属、Ｂａｃｔｅｒｏｉｄｅｓ属、及びＲｏｓｅｂｕｒｉａ属からなる群から選択される細菌をさらに含む、請求項１に記載の経口カプセル。
- 精製されたＦａｅｃａｌｉｂａｃｔｅｒｉｕｍ株と精製されたＯｄｏｒｉｂａｃｔｅｒ ｓｐｌａｎｃｈｎｉｃｕｓを含む糞便微生物調製物、及びＦａｅｃａｌｉｂａｃｔｅｒｉｕｍ増殖刺激剤を含む薬学的組成物の、その必要のあるヒト対象における炎症性腸疾患（ＩＢＤ）を治療するための治療的適用のための医薬の製造のための使用であって、前記糞便微生物調製物が、Ｆｕｓｏｂａｃｔｅｒｉｕｍ属及びＲｕｍｉｎｏｃｏｃｃｕｓ属を欠き、前記薬学的組成物が、薬学的に活性な用量を含む、使用。
- 前記Ｆａｅｃａｌｉｂａｃｔｅｒｉｕｍ増殖刺激剤が、第２の組成物において前記対象に投与される、請求項７に記載の薬学的組成物の使用。
- 前記ＩＢＤが、潰瘍性大腸炎である、請求項７に記載の薬学的組成物の使用。
- 前記治療が、前記ヒト対象に抗生物質事前治療を投与することをさらに含む、請求項７に記載の薬学的組成物の使用。
- 前記増殖刺激剤が、リンゴペクチン、Ｎ−アセチルグルコサミン、システイン、グルタチオン、リボフラビン、およびフラビンからなる群から選択される、請求項７に記載の薬学的組成物の使用。
- 前記糞便微生物調製物が、複数の精製されたＦａｅｃａｌｉｂａｃｔｅｒｉｕｍ株を含む、請求項７に記載の薬学的組成物の使用。
- 前記糞便微生物調製物が、Ｅｕｂａｃｔｅｒｉｕｍ ｒｅｃｔａｌｅ、Ａｋｋｅｒｍａｎｓｉａ属、Ａｌｉｓｔｉｐｅｓ属、Ｂａｃｔｅｒｏｉｄｅｓ属、及びＲｏｓｅｂｕｒｉａ属からなる群から選択される細菌をさらに含む、請求項７に記載の薬学的組成物の使用。
- 前記ヒト対象の腸におけるＦｕｓｏｂａｃｔｅｒｉｕｍ種の増殖を阻害またはアンタゴナイズする、請求項７に記載の薬学的組成物の使用。
- 前記Ｆａｅｃａｌｉｂａｃｔｅｒｉｕｍ株が、Ｆａｅｃａｌｉｂａｃｔｅｒｉｕｍ ｐｒａｕｓｎｉｔｚｉｉである、請求項７に記載の薬学的組成物の使用。
- 精製されたＦａｅｃａｌｉｂａｃｔｅｒｉｕｍ株と精製されたＯｄｏｒｉｂａｃｔｅｒ ｓｐｌａｎｃｈｎｉｃｕｓを含む糞便微生物調製物を含む凍結乾燥薬学的組成物を含むキットであって、前記糞便微生物調製物が、Ｆｕｓｏｂａｃｔｅｒｉｕｍ属及びＲｕｍｉｎｏｃｏｃｃｕｓ属を欠き、少なくとも１種のＦａｅｃａｌｉｂａｃｔｅｒｉｕｍ種のための１種以上の増殖刺激剤をさらに含む、キット。
- 前記１種以上の増殖刺激剤が、第２の組成物において前記キットに存在する、請求項１６に記載のキット。
- 前記糞便微生物調製物が、複数の精製されたＦａｅｃａｌｉｂａｃｔｅｒｉｕｍ株を含む、請求項１６に記載のキット。
- 前記Ｆａｅｃａｌｉｂａｃｔｅｒｉｕｍ株が、Ｆａｅｃａｌｉｂａｃｔｅｒｉｕｍ ｐｒａｕｓｎｉｔｚｉｉである、請求項１６に記載のキット。
- 前記増殖刺激剤が、リンゴペクチン、Ｎ−アセチルグルコサミン、システイン、グルタチオン、リボフラビン、およびフラビンからなる群から選択される、請求項１６に記載のキット。
- 前記増殖刺激剤が、食物繊維である、請求項１に記載の経口カプセル。
- 前記増殖刺激剤が、食物繊維である、請求項７に記載の薬学的組成物の使用。
- 前記増殖刺激剤が、食物繊維である、請求項１６に記載のキット。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662344053P | 2016-06-01 | 2016-06-01 | |
| US62/344,053 | 2016-06-01 | ||
| PCT/US2017/035449 WO2017210428A1 (en) | 2016-06-01 | 2017-06-01 | Compositions and methods for treating inflammatory bowel diseases (ibds) and other disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019520340A JP2019520340A (ja) | 2019-07-18 |
| JP2019520340A5 true JP2019520340A5 (ja) | 2020-08-13 |
Family
ID=60479147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018562993A Pending JP2019520340A (ja) | 2016-06-01 | 2017-06-01 | 炎症性腸疾患（ｉｂｄ）および他の障害を治療するための組成物および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20170348360A1 (ja) |
| EP (1) | EP3462882A4 (ja) |
| JP (1) | JP2019520340A (ja) |
| CN (1) | CN109803534A (ja) |
| AU (1) | AU2017274416C1 (ja) |
| CA (1) | CA3026414A1 (ja) |
| WO (1) | WO2017210428A1 (ja) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6856968B2 (ja) | 2015-05-22 | 2021-04-14 | アリゾナ ボード オブ リージェンツ オン ビハーフ オブ アリゾナ ステート ユニバーシティ | 自閉症スペクトラム障害および関連する症候を治療するための方法 |
| US20170360848A1 (en) | 2016-06-15 | 2017-12-21 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods for treating autism spectrum disorder and associated symptoms |
| WO2018071537A1 (en) | 2016-10-11 | 2018-04-19 | Crestovo Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
| US11213549B2 (en) | 2016-10-11 | 2022-01-04 | Finch Therapeutics Holdings Llc | Compositions and method for treating primary sclerosing cholangitis and related disorders |
| CA3058943C (en) | 2017-04-03 | 2023-10-17 | Gusto Global, Llc | Rational design of microbial-based biotherapeutics |
| JP2020513018A (ja) | 2017-04-05 | 2020-04-30 | クレストヴォ・ホールディングス・エルエルシー | パーキンソン病（ｐｄ）および関連する障害を治療するための組成物および方法 |
| US11040073B2 (en) | 2017-04-05 | 2021-06-22 | Finch Therapeutics Holdings Llc | Compositions and methods for treating diverticulitis and related disorders |
| EP3630190B1 (en) | 2017-05-26 | 2024-02-21 | Finch Therapeutics Holdings LLC | Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same |
| WO2018230695A1 (ja) * | 2017-06-16 | 2018-12-20 | ビオフェルミン製薬株式会社 | 脂肪関連疾患及び／又は炎症の予防又は治療剤 |
| WO2018236979A1 (en) * | 2017-06-20 | 2018-12-27 | Cornell University | PROBIOTIC COMPOSITIONS AND METHODS |
| CN111328284A (zh) | 2017-08-07 | 2020-06-23 | 芬奇治疗公司 | 用于维持和恢复健康的肠道屏障的组合物和方法 |
| EP3725321A4 (en) * | 2017-12-12 | 2021-09-08 | Morinaga Milk Industry Co., Ltd. | COMPOSITION WITH A BACTERIUM OF THE GENUS BIFIDOBACTERIUM AS THE ACTIVE SUBSTANCE |
| GB2585291B (en) * | 2018-02-02 | 2023-07-19 | Univ Hong Kong Chinese | Fecal fungome and therapeutic efficacy of fecal microbiota transplantation |
| WO2019157566A1 (en) * | 2018-02-16 | 2019-08-22 | St Vincent's Hospital (Melbourne) Limited | Compositions and methods for promoting gut health |
| AU2019253616A1 (en) * | 2018-04-13 | 2020-11-05 | Med-Life Discoveries Lp | Long chain dicarboxylic fatty acid (LCDFA) producing microbes and uses thereof |
| CN110396538B (zh) * | 2018-04-24 | 2023-05-23 | 深圳华大生命科学研究院 | 偏头痛生物标志物及其用途 |
| US11166990B2 (en) | 2018-07-13 | 2021-11-09 | Finch Therapeutics Holdings Llc | Methods and compositions for treating ulcerative colitis |
| CN113728088A (zh) * | 2018-09-13 | 2021-11-30 | 组装生物科学公司 | 治疗胃肠障碍和炎性障碍的方法和组合物 |
| KR20210065969A (ko) | 2018-09-27 | 2021-06-04 | 핀치 테라퓨틱스 홀딩스 엘엘씨 | 간질 및 관련 장애를 치료하기 위한 조성물 및 방법 |
| US20220218761A1 (en) * | 2019-05-06 | 2022-07-14 | The General Hospital Corporation | Monitoring and altering the gut microbiome in disease |
| CN114364388A (zh) * | 2019-07-11 | 2022-04-15 | 安东尼·米利斯 | 一种增强微生物植入的肠黏膜制备方法 |
| CN110541026A (zh) * | 2019-08-17 | 2019-12-06 | 昆明医科大学第一附属医院 | 一种检测溃疡性结肠炎的生物标志物及应用 |
| AU2020365134A1 (en) * | 2019-10-18 | 2022-06-02 | Thaena Inc. | Fecal-derived sterile postbiotic composition and method therefor |
| EP3839072A1 (en) * | 2019-12-17 | 2021-06-23 | Luxia Scientific | Bacterial combinations predictive of the activity of multiple sclerosis |
| EP3838276A1 (en) * | 2019-12-17 | 2021-06-23 | Exeliom Biosciences | Association of faecalibacterium prausnitzii strain cncm i-4573 with pentasa® for the treatment and prevention of gastrointestinal inflammation |
| WO2021161312A1 (en) * | 2020-02-11 | 2021-08-19 | The E. Wolfson Medical Center | A method effective for treating ulcerative colitis |
| US20230087012A1 (en) * | 2020-02-14 | 2023-03-23 | Cornell University | Transferable microbiota for the treatment of ulcerative colitis |
| CN111304120B (zh) * | 2020-02-24 | 2021-07-23 | 浙江大学 | Blautia sp B2132菌在预防和/或治疗炎症性肠病中的应用 |
| BR112022019930A2 (pt) * | 2020-04-01 | 2022-12-13 | The E Wolfson Medical Center | Dieta para colite ulcerativa, fórmulas, produtos e métodos dos mesmos |
| KR102169794B1 (ko) * | 2020-06-24 | 2020-10-27 | 주식회사 엔테로바이옴 | 신규한 피칼리박테리움 프로스니치 균주 eb-fpdk11 및 그의 용도 |
| KR102169795B1 (ko) * | 2020-06-24 | 2020-10-27 | 주식회사 엔테로바이옴 | 신규한 피칼리박테리움 프로스니치 eb-fpdk9 균주 및 그의 용도 |
| CN111888381A (zh) * | 2020-09-18 | 2020-11-06 | 广西细微生物科技有限责任公司 | 一种肠道微生物移植工艺 |
| EP4219681A1 (en) * | 2020-09-28 | 2023-08-02 | CJ Bioscience, Inc. | Composition for diagnosis or treatment of inflammatory diseases, comprising microorganism |
| WO2022212510A1 (en) * | 2021-04-01 | 2022-10-06 | Medibeacon Inc. | Methods of monitoring mucosal healing |
| EP4082545A1 (en) * | 2021-04-27 | 2022-11-02 | Diotheris | Combination product and methods for preventing the emergence of antibiotic-resistant bacteria under antibiotic treatment |
| KR102337993B1 (ko) * | 2021-10-27 | 2021-12-14 | 주식회사 바이오뱅크힐링 | 클로스트리디움 렙텀 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 |
| CN113974159B (zh) * | 2021-11-02 | 2023-06-27 | 美益添生物医药(武汉)有限公司 | 齿叶乳香树树脂在制备促进肠道有益菌增殖的产品中的应用 |
| TW202400235A (zh) * | 2022-05-13 | 2024-01-01 | 國立大學法人東京大學 | 治療或診斷炎症性腸疾病(ibd)之方法及組合物 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1510821A1 (en) * | 2003-08-27 | 2005-03-02 | Universiteit Utrecht Holding B.V. | Diagnosis and treatment of mycobacterial infections |
| RU2013109251A (ru) * | 2010-08-04 | 2014-09-10 | Томас Джулиус БОРОДИ | Композиции для трансплантации фекальной флоры и способы их получения и применения и устройства для их доставки |
| US9968638B2 (en) * | 2011-03-09 | 2018-05-15 | Regents Of The University Of Minnesota | Compositions and methods for transplantation of colon microbiota |
| US20140342438A1 (en) * | 2011-09-14 | 2014-11-20 | University Of Guelph | Media supplements and methods to culture human gastrointestinal anaerobic microorganisms |
| US20150283144A1 (en) * | 2012-11-01 | 2015-10-08 | Rijksuniversiteit Groningen | Methods and compositions for stimulating beneficial bacteria in the gastrointestinal tract |
| AU2014212003C1 (en) * | 2013-02-04 | 2020-07-16 | Seres Therapeutics, Inc. | Compositions and methods for inhibition of pathogenic bacterial growth |
| JP2016511272A (ja) * | 2013-03-05 | 2016-04-14 | レイクスユニフェルシテイト フローニンゲン | 炎症を抑制するためのフィーカリバクテリウム・パラウスニッチィーｈｔｆ−ｆ（ｄｓｍ２６９４３）の使用 |
| US20150246081A1 (en) * | 2014-03-03 | 2015-09-03 | Shayne Kenneth Morris | Probiotics with methods for growth and use separately and in combination |
| US9783858B2 (en) * | 2014-04-02 | 2017-10-10 | Northwestern University | Altered microbiome of chronic pelvic pain |
| MA41020A (fr) * | 2014-11-25 | 2017-10-03 | Evelo Biosciences Inc | Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome |
-
2017
- 2017-06-01 AU AU2017274416A patent/AU2017274416C1/en active Active
- 2017-06-01 JP JP2018562993A patent/JP2019520340A/ja active Pending
- 2017-06-01 CN CN201780043664.8A patent/CN109803534A/zh active Pending
- 2017-06-01 US US15/611,338 patent/US20170348360A1/en not_active Abandoned
- 2017-06-01 EP EP17807481.1A patent/EP3462882A4/en not_active Withdrawn
- 2017-06-01 CA CA3026414A patent/CA3026414A1/en not_active Abandoned
- 2017-06-01 WO PCT/US2017/035449 patent/WO2017210428A1/en unknown
-
2020
- 2020-12-28 US US17/135,544 patent/US20210106629A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019520340A5 (ja) | ||
| Ojetti et al. | The effect of Lactobacillus reuteri supplementation in adults with chronic functional constipation: a randomized, double-blind, placebo-controlled trial | |
| Dixit et al. | Restoration of dysbiotic human gut microbiome for homeostasis | |
| Bergogne-Berezin | Treatment and prevention of antibiotic associated diarrhea | |
| AU2010339573B2 (en) | Compositions and method for treatment and prophylaxis of inflammatory bowel disease | |
| JP2016529309A5 (ja) | ||
| US20210030818A1 (en) | Compositions for use in balancing microbiome | |
| RU2011139211A (ru) | Бактериальные штаммы, обладающие высокой противовоспалительной активностью | |
| JP2019525944A5 (ja) | ||
| BRPI0517273B1 (pt) | composição contendo uma mistura de três bactérias probióticas, uso desta para a prevenção e/ou tratamento de infecções do trato respiratório superior e na regularização da funcionalidade intestinal do organismo acometido por essas patologias e kit contendo uma mistura de três bactérias probióticas | |
| BR112012018813B1 (pt) | composição compreendendo cepas bacterianas com atividade anti-inflamatória, imunomoduladora, antiibs ou antidistensão abdominal, uso das mesmas, bem como produtos farmacêutico, veterinário e comestível compreendendo a referida composição | |
| US11801275B2 (en) | Compositions and methods for common colds | |
| CN109069464A (zh) | 一种调节肠道微生物群的治疗方法 | |
| CN109789171A (zh) | 用于治疗重度抑郁症的组合物 | |
| BR112020019979A2 (pt) | Composições e métodos para tratamento de doenças inflamatórias intestinais | |
| US11433102B2 (en) | Compositions and methods for treating Parkinson's disease (PD) and related disorders | |
| US10960034B2 (en) | MRSA infection protective agent | |
| BRPI0407176B8 (pt) | composições compreendendo uma ou mais cepas de bifidobacterium e seus usos | |
| WO2021097288A1 (en) | Compositions and methods for treating neurodegenerative diseases | |
| ITMI950378A1 (it) | Associazioni di fermenti lattici e lisati di saccaromiceti loro uso terapeutico e composizioni che le contengono | |
| KR20230097085A (ko) | 항생제에 대한 노출 후 소화관 마이크로바이옴을 재균형화시키기 위한 비타민의 직접 전달 | |
| CN114585380A (zh) | 胃肠健康组合物 | |
| CN111436612A (zh) | 一种体内酵素及其制备方法与在抑制新型病毒方面的应用 | |
| BR112020006694A2 (pt) | uma composição farmacêutica compreendendo um probiótico e um prebiótico para prevenir a aquisição de ou para tratar infecções resistentes a fármacos | |
| US20180289745A1 (en) | Compositions and Methods for Treating Parkinson's Disease (PD) and Related Disorders |